In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli

  • Antimicrob Agents Chemother. 2018 Dec 21;63(1):e01832-18. doi: 10.1128/AAC.01832-18.
James A Karlowsky  1 ,  Heather J Adam  1 ,  Melanie R Baxter  1 ,  Andrew J Denisuik  1 ,  Philippe R S Lagacé-Wiens  1 ,  Andrew J Walkty  1 ,  Sailaja Puttagunta  2 ,  Michael W Dunne  2 ,  George G Zhanel  3
Affiliations
  • 1. Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
  • 2. Iterum Therapeutics, Old Saybrook, Connecticut, USA.
  • 3. Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada [email protected].
PMID: 30397056 DOI: 10.1128/AAC.01832-18
Abstract

The in vitro activity of sulopenem was assessed against a collection from 2014 to 2016 of 539 urinary isolates of Escherichia coli from Canadian patients by using CLSI-defined broth microdilution methodology. A concentration of sulopenem 0.03 µg/ml inhibited both 50% (MIC50) and 90% (MIC90) of isolates tested; sulopenem MICs ranged from 0.015 to 0.25 µg/ml. The in vitro activity of sulopenem was unaffected by nonsusceptibility to trimethoprim-sulfamethoxazole and/or ciprofloxacin, multidrug-resistant phenotypes, extended-spectrum β-lactamases, or AmpC β-lactamases.

Keywords
Escherichia coli; penem; sulopenem; urinary.
Products